Effect of Novel AKT Inhibitor Vevorisertib as Single Agent and in Combination with Sorafenib on Hepatocellular Carcinoma in a Cirrhotic Rat Model

Effect of Novel AKT Inhibitor Vevorisertib as Single Agent and in Combination with Sorafenib on Hepatocellular Carcinoma in a Cirrhotic Rat Model

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide. The AKT pathway is often activated in HCC cases, and a longer exposure to tyrosine kinase inhibitors such as sorafenib may lead to over-activation of the AKT pathway, leading to HCC resistance. Here, w...

Full description

Bibliographic Details
Main Authors: Keerthi Kurma, Ayca Zeybek Kuyucu, Gaël S. Roth, Nathalie Sturm, Marion Mercey-Ressejac, Giovanni Abbadessa, Yi Yu, Herve Lerat, Patrice N. Marche, Thomas Decaens, Zuzana Macek Jilkova
Format: Article
Language:English
Published: MDPI AG 2022-12-01
Series:International Journal of Molecular Sciences
Subjects:
HCC
DEN-induced cirrhotic rat model of HCC
liver
fibrosis
vevorisertib
AKT pathway
Online Access:https://www.mdpi.com/1422-0067/23/24/16206

Internet

https://www.mdpi.com/1422-0067/23/24/16206

Similar Items